MAR 15, 2018 6:52 PM PDT

Light controls variants of active ingredient in cannabis

WRITTEN BY: Invisiverse

Chemists have synthesized several variants of THC, the active ingredient in cannabis. The ability to alter its structure with light has led to a new tool for more effectively studying the body’s own cannabinoid system.

When many people hear the abbreviation THC (tetrahydrocannabinol), they immediately think of smoking marijuana and intoxication. But the substance is also of interest to medicine—when given to people suffering from serious illnesses, it relieves muscle cramps, pain, loss of appetite, and nausea.

THC works by binding to the corresponding cannabinoid-1 (CB1) receptors, which are located in the cell membrane and are present in large numbers in the central and peripheral nervous system. CB1 receptors play a major role in memory, motor coordination, mood, and cognitive processes.

When a THC molecule binds to one of these CB1 receptors, it changes form, triggering a cascade of various signals inside the cell. However, it is still hard to study CB1 receptors and their manifold functions, because cannabinoids such as THC are highly lipophilic, so they frequently embed themselves in the membranes made of fat molecules in an uncontrolled way.

To be able to use THC or variants of it more precisely for pharmaceutical and medical applications, it is important to gain a better understanding of CB1 receptors.

THC ‘antenna’

To study the diverse interactions between CB1 receptors and cannabinoids, ETH Zurich professor Erick Carreira and colleagues synthesized THC molecules and report the work in the Journal of the American Chemical Society.

The chemists synthesized four variants, or derivatives, of THC by attaching a light-sensitive “antenna” to the THC molecule. This antenna makes it possible to use light of a specific wavelength to precisely manipulate the altered molecule. Ultraviolet light changes the spatial structure of the antenna, and this change can be reversed again with blue light.

The researchers tested two of these derivatives in a living cell culture. The derivatives docked with CB1 receptors in the same way as naturally occurring THC. When the researchers irradiated the THC derivative with ultraviolet light, its structure altered just as the researchers expected, consequently activating the CB1 receptor. This triggers reactions such as the opening of the potassium ion channels located in the cell membrane, which causes potassium ions to flow out of the cell. The researchers were able to measure this with an electrode inserted into the cell.

When irradiated with blue light, the THC derivative returned to its original form, disabling the CB1 receptor as a result. The ion channels closed and the flow of potassium stopped. The researchers were able to activate and deactivate these processes using the corresponding colored pulses of light.

“This work is our successful proof of principle: light-sensitive THC variants are a suitable tool for controlling and influencing CB1 receptors,” says Michael Schafroth, a doctoral student with Carreira and a major contributor to the study.

Drug development

Additional projects using the findings are in progress: for example, another doctoral student in Carreira’s group, Roman Sarott, is working on synthesizing additional THC derivatives that react to long-wavelength red light. “Red light penetrates deeper into tissue than blue light,” says Sarott. “If we want to study CB1 receptors in a living organism, we need molecules that are sensitive to red light.”

Many cultures have long known of the intoxicating and therapeutic effect of THC. The identification of THC eventually led to the discovery of the endocannabinoid system, which involves the body’s native as well as exogenous substances in the cannabinoids class as well as their receptors in the body.

The pharmaceutical industry is also interested in gaining a better understanding of the endocannabinoid system so that it can better use specific components for pharmaceutical purposes. The system is considered a possible starting point for treatments for addiction, obesity, depression, and even Alzheimer’s and Parkinson’s.

 

This article was originally posted on futurity.org

About the Author
You May Also Like
MAY 28, 2020
Cannabis Sciences
Cannabis-Free CBD More Effective than Regular CBD
MAY 28, 2020
Cannabis-Free CBD More Effective than Regular CBD
Commonly known to come from the cannabis plant or hemp, cannabidiol (CBD) can also be found in a range of other plants. ...
JUN 07, 2020
Cannabis Sciences
Should You Smoke Cannabis Seeds and Stems?
JUN 07, 2020
Should You Smoke Cannabis Seeds and Stems?
When smoking cannabis, people typically use either the flower, buds, or leaves. But what about the seeds and stems? Can ...
JUN 30, 2020
Health & Medicine
UK Loosens Regulation on Prescription CBD for Epilepsy
JUN 30, 2020
UK Loosens Regulation on Prescription CBD for Epilepsy
Epidyolex-the epilepsy drug that contains the non-psychoactive cannabis chemical cannabidiol, or CBD-has been changed fr ...
AUG 05, 2020
Health & Medicine
Regular Female Cannabis Users Report Greater Sexual Satisfaction
AUG 05, 2020
Regular Female Cannabis Users Report Greater Sexual Satisfaction
The impact of cannabis on female sexual function has always been unclear, but a study published recently in Sexual Medic ...
AUG 16, 2020
Cannabis Sciences
Cannabinoids May Interact with Prescribed Medications
AUG 16, 2020
Cannabinoids May Interact with Prescribed Medications
Despite the growing popularity of cannabis products, information is currently limited on how they may interact with othe ...
SEP 21, 2020
Cannabis Sciences
Why Do We Build Tolerance to Cannabis?
SEP 21, 2020
Why Do We Build Tolerance to Cannabis?
Many notice that after regularly smoking cannabis, it takes more and more to feel its effects- if any at all. While abst ...
Loading Comments...